Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Energy and Commerce’s health care plans

This article was originally published in The Tan Sheet

Executive Summary

The House Energy and Commerce Committee's oversight plan for the 111th Congress includes assessing "whether necessary safeguards for imported drugs are in place," which is a focus of the FDA Globalization Act co-sponsored by former committee chairman John Dingell, D-Mich. (1"The Tan Sheet" Feb. 2, 2009, p. 6). Energy and Commerce also will examine manufacturing practices for Rx and nonprescription drugs and investigate off-label marketing of Rx drugs. House committees must submit oversight plans to the Oversight and Government Reform Committee and the House Administration Committee near the start of each session. The plans outline topics committees want to address, but the panels can narrow or expand their work during a session

You may also be interested in...



Salmonella Problem Stirs Food Safety Bills, Hearing From Energy & Commerce

At an upcoming hearing, House Energy and Commerce Committee leaders will question executives from labs that tested ingredients at the peanut processing facility linked to widespread recalls due to salmonella contamination

Boost For Oral SERDs As Menarini/Radius’ Orserdu Becomes First Approved For Breast Cancer

The firms’ Orserdu has won a US thumbs up for the treatment of ESR1-mutated advanced or metastatic breast cancer, marking a positive breakthrough for the challenging SERD drug class.

Pfizer In Pole Position To Benefit From Novartis Sickle Cell Drug Setback

Pfizer joined Novartis as the market leader in sickle cell disease when it acquired Global Blood Therapeutics last year. The US giant's Oxbryta may now move ahead following a clinical and regulatory setback for the Swiss major's Adakveo.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS102632

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel